-
Effects of sacubitril/valsartan according to background beta-blocker therapy in patients with heart failure and reduced ejection fraction: Insights from PARADIGM-HF Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-11-19 Sharmistha Datta Gupta, Jawad H. Butt, Eoghan G.M. McMurray, Atefeh Talebi, Shingo Matsumoto, Adel R. Rizkala, Alasdair D. Henderson, Akshay S. Desai, Martin Lefkowitz, Milton Packer, Jean L. Rouleau, Scott D. Solomon, Karl Swedberg, Michael R. Zile, Pardeep S. Jhund, John J.V. McMurray
-
Hypertensive pregnancy disorder, an under-recognized women specific risk factor for heart failure? Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-11-19 Chahinda Ghossein-Doha, Basky Thilaganathan, Arthur Jason Vaught, Joan E. Briller, Jolien W. Roos-Hesselink
-
A functional role for spontaneously occurring natural anti-transthyretin antibodies from patients with transthyretin cardiac amyloidosis Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-11-19 Ortal Tuvali, Michael Fassler, Sorel Goland, Clara Benaim, Sara Shimoni, Jacob George
Introduction Transthyretin cardiac amyloidosis (ATTR-CA) is a progressive disease that results from the accumulation of transthyretin (TTR) fibrils in the extracellular space of the myocardium, leading to heart failure.1 The pathogenesis of ATTR-CA results from a reduction in cardiac compliance due to amyloid fibril deposition, but recent observations suggest that soluble TTR intermediate oligomers
-
Treat or not treat COVID-19 with combined renin–angiotensin system and neprilysin inhibition: Have we found a solution? Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-11-19 Insa E. Emrich, Michael Böhm
Since 2019, coronavirus disease 2019 (COVID-19) has affected millions of individuals worldwide, leading to multiple deaths and numerous long-term multiorgan sequelae. In patients with COVID-19, cardiovascular diseases, including heart failure (HF), are common and associated with an increased risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections1 and high mortality rates.2
-
Knowledge and application of ESC/HFA guidelines in the management of advanced heart failure Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-11-19 Guillaume Baudry, Nicolas Girerd, Maja Cikes, Maria Generosa Crespo-Leiro, Kevin Damman, Clément Delmas, Stamatis Adamopoulos, Sanem Nalbantgil, Hoong Sern Lim, Frank Ruschitzka, Marco Metra, Finn Gustafsson
-
Malnutrition and severe heart failure in real-world study settings. Letter regarding the article ‘Impact of malnutrition in patients with severe heart failure’ Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-11-19 Meng-Che Wu, Shih-Chi Yang, Shuo-Yan Gau
Click on the article title to read more.
-
Association between locomotor muscle quality and cardiac function during exercise in heart failure with preserved ejection fraction Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-11-19 Salaheddin M. Sharif, Joshua R. Smith, Barry A. Borlaug, Thomas P. Olson
-
Decreased left ventricular ejection fraction is associated with increased mortality in sepsis: A retrospective cohort study Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-11-19 August A. Longino, Jacqueline A. Urban, Katharine C. Martin, Katarina R. Leyba, Theresa N. Thai, Ivor S. Douglas, David S. Raymer
Click on the article title to read more.
-
Congenitally Corrected Transposition of the Great Arteries: The Impact of Anatomic vs Physiologic Repair J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-11-20 Tara Karamlou, Justin Robinson
-
Adding AI to the Toolkit for Patients With Implantable Cardioverter-Defibrillators J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-11-20 Archana Ramireddy, Eric D. Braunstein, Sumeet S. Chugh
Section snippets Funding Support and Author DisclosuresThe authors have reported that they have no relationships relevant to the contents of this paper to disclose.
-
Advanced Imaging Assessment of the Impact of Tricuspid Regurgitation on Cardiac Remodeling: The TRILUMINATE Pivotal Imaging Substudy J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-11-20 João L. Cavalcante, Markus Scherer, Miho Fukui, Stamatios Lerakis, Serge Harb, Amit Pursnani, Jonathan G. Schwartz, Samir Kapadia, Mark J. Ricciardi, Omar Khalique, Susheel Kodali, Dipan Shah, Steven H. Little, Nishant Sekaran, Brian Whisenant, Peter Flueckiger, Pradeep Yadav, Abbas Emaminia, Wayne Batchelor, Peter Kellman, Paul Sorajja
-
Machine Learning-Based Prediction of Death and Hospitalization in Patients With Implantable Cardioverter Defibrillators J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-11-20 Lindsey Rosman, Rachel Lampert, Kaicheng Wang, Anil K. Gehi, James Dziura, Elena Salmoirago-Blotcher, Cynthia Brandt, Samuel F. Sears, Matthew Burg
-
Getting Imaging Right: Multimodal Assessment of Right-Sided Heart Function in Patients Undergoing Tricuspid Repair J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-11-20 Mathias Orban, Nicole Karam, Lukas Stolz, Philipp Lurz, Jörg Hausleiter
Section snippets Funding Support and Author DisclosuresDr Karam has received consultant fees from Edwards Lifesciences, Boston Scientific, and Medtronic; and has received proctor fees from Abbott. Dr Stolz received speaker honoraria from Edwards Lifesciences. Dr Lurz has received institutional fees and research grants from Abbott Cardiovascular, Edwards Lifesciences, and ReCor; has received honoraria
-
Anatomic and Physiologic Repair of Congenitally Corrected Transposition of the Great Arteries J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-11-20 Kirolos A. Jacob, Jürgen Hörer, Viktor Hraska, Valirie N. Agbor, Saniyé Duchateau, Abraham van Wijk, David J. Barron, Paul H. Schoof
-
Unlocking excellence in health care: the power of inclusive and sensitive language in medicine Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-11-20 Sarah M. Birkhoelzer, Sonia S. Anand
This call to action aims to increase awareness of inclusive language in medicine to enhance the experiences of patients and staff and improve health outcomes. Recognizing that terms change, we urge all health-care professionals to advocate for their colleagues and patients. This responsibility to educate the community should not fall exclusively onto marginalized communities.
-
Non-bacterial thrombotic endocarditis: a clinical and pathophysiological reappraisal Eur. Heart J. (IF 37.6) Pub Date : 2024-11-20 Omair Ahmed, Nicholas E King, Muhammad Ahmad Qureshi, Abira Afzal Choudhry, Muhammad Osama, Carl Zehner, Abdelrahman Ali, Ihab R Hamzeh, Nicolas L Palaskas, Kara A Thompson, Efstratios Koutroumpakis, Anita Deswal, Syed Wamique Yusuf
Non-bacterial thrombotic endocarditis (NBTE), formerly recognized as marantic endocarditis, represents a rare cardiovascular pathology intricately linked with hypercoagulable states, notably malignancy and autoimmune disorders. Characterized by the development of sterile vegetations comprised of fibrin and platelets on cardiac valves, NBTE poses a diagnostic challenge due to its resemblance to infective
-
5-Year Results From the AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-11-18 Dhanunjaya Lakkireddy, Christopher R. Ellis, David Thaler, Vijendra Swarup, Alok Gambhir, James Hermiller, Jens Erik Nielsen-Kudsk, Stephen Worthley, Devi Nair, Boris Schmidt, Rodney Horton, Nigel Gupta, Jordan A. Anderson, Hong Zhao, Mohamad Alkhouli, Stephan Windecker
-
Semaglutide Improves Cardiovascular Outcomes in Patients With History of Coronary Artery Bypass Graft and Obesity J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-11-18 Subodh Verma, Scott Emerson, Jorge Plutzky, Steven E. Kahn, Signe Stensen, Peter E. Weeke, Derrick Musinga, Paul Poirier, Ildiko Lingvay, A. Michael Lincoff
No Abstract
-
Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-11-18 Christopher M. Kramer, Barry A. Borlaug, Michael R. Zile, Dustin Ruff, Joseph M. DiMaria, Venu Menon, Yang Ou, Angela M. Zarante, Karla C. Hurt, Masahiro Murakami, Milton Packer
-
Aortic Valve Replacement Versus Clinical Surveillance in Asymptomatic Severe Aortic Stenosis: A Systematic Review and Meta-Analysis J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-11-18 Philippe Généreux, Marko Banovic, Duk-Hyun Kang, Gennaro Giustino, Bernard D. Prendergast, Brian R. Lindman, David E. Newby, Philippe Pibarot, Björn Redfors, Neil J. Craig, Jozef Bartunek, Allan Schwartz, Roxanna Seyedin, David J. Cohen, Bernard Iung, Martin B. Leon, Marc R. Dweck
BackgroundCurrent guidelines recommend a strategy of clinical surveillance (CS) for patients with asymptomatic severe aortic stenosis (AS) and normal left ventricular ejection fraction. ObjectivesTo conduct a study-level meta-analysis of randomized controlled trials (RCTs) evaluating the effect of early aortic valve replacement (AVR) compared with CS in patients with asymptomatic severe AS. MethodsStudies
-
Amulet LAAO 5-year Outcomes: Best in Class or Class Effect? J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-11-18 Daniel J. Friedman, James V. Freeman
No Abstract
-
Charting the future of cardiology with large language model artificial intelligence Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-11-19 Ramsey M. Wehbe
-
Cholesterol crystals in the pathogenesis of atherosclerosis Nat. Rev. Cardiol. (IF 41.7) Pub Date : 2024-11-18 Yvonne Baumer, Jason Irei, William A. Boisvert
-
STOPDAPT-3 one-year results support similar efficacy and safety of aspirin and clopidogrel after percutaneous coronary intervention. Eur. Heart J. (IF 37.6) Pub Date : 2024-11-19 Rocco Vergallo,Carlo Patrono
-
Stroke risk in device-detected atrial fibrillation is modulated by the continuum of vascular disease burden. Eur. Heart J. (IF 37.6) Pub Date : 2024-11-19 Dominik Linz,Sevasti-Maria Chaldoupi
-
First past the post: research on endurance exercise wins the Desmond Julian Award. Eur. Heart J. (IF 37.6) Pub Date : 2024-11-19 Judith Ozkan
-
Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients with Heart Failure J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-11-18 Mikhail N. Kosiborod, David Z.I. Cherney, Akshay S. Desai, Jeffrey M. Testani, Subodh Verma, Khaja Chinnakondepalli, David Dolling, Shachi Patel, Magnus Dahl, James M. Eudicone, Lovisa Friberg, Mario Ouwens, Murillo O. Antunes, Kim A. Connelly, Vagner Madrini, Luca Kuthi, Anuradha Lala, Miguel Lorenzo, Patrícia O. Guimarães, Marta Cobo Marcos, Mark C. Petrie
BackgroundMineralocorticoid receptor antagonists (MRA) improve outcomes in patients with heart failure and reduced ejection fraction (HFrEF) but are underused in clinical practice. Observational data suggest that hyperkalemia is the leading obstacle for the suboptimal use of MRA. ObjectivesWe evaluated the effects of sodium zirconium cyclosilicate (SZC) in optimizing use of spironolactone among participants
-
Outpatient Worsening Heart Failure in Patients with Transthyretin Amyloidosis with Cardiomyopathy in the HELIOS-B Trial J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-11-18 Marianna Fontana, Mathew S. Maurer, Julian D. Gillmore, Shaun Bender, Emre Aldinc, Satish A. Eraly, Patrick Y. Jay, Scott D. Solomon
BACKGROUNDTransthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a fatal disease, caused by misfolded transthyretin depositing as amyloid fibrils in the heart. Because disease progression is common, practical and sensitive methods are needed to monitor patients and optimize treatment decisions. Outpatient worsening heart failure (HF) (oral loop diuretic intensification or initiation) is simple
-
-
Contents J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-11-18
Section snippets Associations of Self-Reported Race, Social Determinants of Health, and Polygenic Risk With Coronary Heart Disease 2157Kristjan Norland, Daniel J. Schaid, Mohammadreza Naderian, Jie Na, Iftikhar J. KulloIn a study of 67,256 All of Us participants, the authors tested the associations of self-reported race/ethnicity, social determinants of health (SDOH), and polygenic risk with coronary
-
Associations of Self-Reported Race, Social Determinants of Health, and Polygenic Risk With Coronary Heart Disease J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-11-18 Kristjan Norland, Daniel J. Schaid, Mohammadreza Naderian, Jie Na, Iftikhar J. Kullo
BackgroundSocial determinants of health (SDOH) influence the risk of common diseases such as coronary heart disease (CHD). ObjectivesThis study sought to test the associations of self-reported race/ethnicity, SDOH, and a polygenic risk score (PRS), with CHD in a large and diverse U.S. cohort. MethodsIn 67,256 All of Us (AoU) participants with available SDOH and whole-genome sequencing data, we ascertained
-
Considering Social and Genetic Factors in Cardiovascular Disease Risk J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-11-18 Nilay S. Shah
-
Answering the Call: Enhancing Telemedicine Reach With Artificial intelligence Integration J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-11-18 Ioannis Skalidis, Niccolo Maurizi, George Dangas, Yiannis S. Chatzizisis
No Abstract
-
Reply: Answering the Call: Enhancing Telemedicine Reach With Artificial intelligence Integration J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-11-18 Adam Hartley, Nasser Alshahrani, Ramzi Y. Khamis
No Abstract
-
Revealing the Hidden Layers: Focus on Social and Psychological Determinants in Congenital Heart Surgery Prognosis J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-11-18 Zhangxin Wen, Sihan Duan, Hong Liu
No Abstract
-
Reply: Revealing the Hidden Layers: Focus on Social and Psychological Determinants in Congenital Heart Surgery Prognosis J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-11-18 Sarah Crook, Brett R. Anderson
No Abstract
-
Glycemic Control and Coronary Stent Failure in Patients With Type 2 Diabetes Mellitus J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-11-18 Chao Liu, Ximing Li, Hongliang Cong
No Abstract
-
Reply: Glycemic Control and Coronary Stent Failure in Patients With Type 2 Diabetes Mellitus J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-11-18 Irene Santos-Pardo, Mikael Andersson Franko, Thomas Nyström
No Abstract
-
Clinical Signs of Congestion in Younger Patients With Decompensated Heart Failure J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-11-18 Jaimie Coburn, Pieter A. Neef, Simon Hobson, Jonathan R. Dalzell
No Abstract
-
Atheroma transcriptomics identifies ARNTL as a smooth muscle cell regulator and with clinical and genetic data improves risk stratification Eur. Heart J. (IF 37.6) Pub Date : 2024-11-18 Sampath Narayanan, Sofija Vuckovic, Otto Bergman, Robert Wirka, Jose Verdezoto Mosquera, Qiao Sen Chen, Damiano Baldassarre, Elena Tremoli, Fabrizio Veglia, Mariette Lengquist, Redouane Aherahrrou, Anton Razuvaev, Bruna Gigante, Hanna M Björck, Clint L Miller, Thomas Quertermous, Ulf Hedin, Ljubica Matic
Background and Aims The role of vascular smooth muscle cells (SMCs) in atherosclerosis has evolved to indicate causal genetic links with the disease. Single cell RNA sequencing (scRNAseq) studies have identified multiple cell populations of mesenchymal origin within atherosclerotic lesions, including various SMC sub-phenotypes, but it is unknown how they relate to patient clinical parameters and genetics
-
Oral anticoagulation and non-steroidal anti-inflammatory drugs: a recipe for bleeding. Eur. Heart J. (IF 37.6) Pub Date : 2024-11-18 William A E Parker,Robert F Storey
-
Bleeding risk using non-steroidal anti-inflammatory drugs with anticoagulants after venous thromboembolism: a nationwide Danish study Eur. Heart J. (IF 37.6) Pub Date : 2024-11-18 Søren Riis Petersen, Kasper Bonnesen, Erik Lerkevang Grove, Lars Pedersen, Morten Schmidt
Background and Aims The bleeding risk of using non-steroidal anti-inflammatory drugs (NSAIDs) in patients treated with oral anticoagulants for venous thromboembolism (VTE) remains unclear. Methods A nationwide cohort study of 51 794 VTE patients initiating oral anticoagulants between 1 January 2012 and 31 December 2022 was conducted. Time-dependent multivariate cause-specific Cox regression was used
-
Effects of Tirzepatide on the Clinical Trajectory of Patients with Heart Failure, a Preserved Ejection Fraction, and Obesity. Circulation (IF 35.5) Pub Date : 2024-11-18 Michael R Zile,Barry A Borlaug,Christopher M Kramer,Seth J Baum,Sheldon E Litwin,Venu Menon,Yang Ou,Govinda J Weerakkody,Karla C Hurt,Chisom Kanu,Masahiro Murakami,Milton Packer,
BACKGROUND Patients with heart failure, a preserved ejection fraction (HFpEF), and obesity have significant disability and suffer frequent exacerbations of heart failure. We hypothesized that tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, would improve a comprehensive suite of clinical endpoints, including measures of health
-
Atrial Arrhythmias After PFO Device Closure: Common, Clinically Important, and Preventable? Circulation (IF 35.5) Pub Date : 2024-11-18 Jonathan M Tobis,John D Carroll
-
Letter by Lucijanic and Krecak Regarding Article, "Clonal Hematopoiesis of Indeterminate Potential With Loss of Tet2 Enhances Risk for Atrial Fibrillation Through Nlrp3 Inflammasome Activation". Circulation (IF 35.5) Pub Date : 2024-11-18 Marko Lucijanic,Ivan Krecak
-
Pulmonary Hypertension: From Therapeutic Nihilism to Multiple Therapeutic Interventions. Circulation (IF 35.5) Pub Date : 2024-11-18 Vallerie V McLaughlin,Marc Humbert
-
Low-Density Lipoprotein Cholesterol Level Distributions Across Different Ages: Implications for Screening Children for Severe and Familial Hypercholesterolemia. Circulation (IF 35.5) Pub Date : 2024-11-18 Junxiu Liu,Brandon K Bellows,David R Jacobs,Jessica G Woo,Elaine M Urbina,Pallavi P Balte,Elizabeth C Oelsner,Dhruv S Kazi,David Siscovick,Norrina B Allen,Jamal S Rana,John T Wilkins,Michael E Hall,Lydia A Bazzano,Trudy L Burns,Stephen R Daniels,Terence Dwyer,Markus Juonala,Olli T Raitakari,Alan R Sinaiko,Julia Steinberger,Alison J Venn,Noora Kartiosuo,Terho Lehtimäki,Costan G Magnussen,Jorma S A Viikari
-
Precision Medicine for Cardiovascular Prevention and Population Health: A Bridge Too Far? Circulation (IF 35.5) Pub Date : 2024-11-18 Fernando R Giugni,Jarett D Berry,Amit Khera,Amil M Shah,James A de Lemos
Precision medicine aims to provide personalized clinical care guided by tools that reflect underlying pathophysiology. The need for such an approach has never been greater in cardiovascular medicine, given the large number of guideline-directed medical therapies available. However, progress has been modest to date with few precision tools available for clinicians. Arguably, cardiovascular prevention
-
Screening for Cardiac Involvement in Carriers of Pathogenic TTR Variants: Proposal for an Approach Based on High-Sensitivity Troponin. Circulation (IF 35.5) Pub Date : 2024-11-18 Alberto Aimo,Chiara Sanguinetti,Maria Franzini
-
Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial. Circulation (IF 35.5) Pub Date : 2024-11-18 Daniel P Judge,Julian D Gillmore,Kevin M Alexander,Amrut V Ambardekar,Francesco Cappelli,Marianna Fontana,Pablo García-Pavía,Justin L Grodin,Martha Grogan,Mazen Hanna,Ahmad Masri,Jose Nativi-Nicolau,Laura Obici,Steen Hvitfeldt Poulsen,Nitasha Sarswat,Keyur Shah,Prem Soman,Ted Lystig,Xiaofan Cao,Kevin Wang,Maria Lucia Pecoraro,Jean-François Tamby,Leonid Katz,Uma Sinha,Jonathan C Fox,Mathew S Maurer
BACKGROUND In the phase 3 randomized controlled study, ATTRibute-CM, acoramidis, a transthyretin (TTR) stabilizer, demonstrated significant efficacy on the primary endpoint. Participants with transthyretin amyloid cardiomyopathy (ATTR-CM) who completed ATTRibute-CM were invited to enroll in an open-label extension study (OLE). We report efficacy and safety data of acoramidis in participants who completed
-
Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results from VALOR-HCM. Circulation (IF 35.5) Pub Date : 2024-11-18 Milind Y Desai,Kathy Wolski,Anjali Owens,Jeffrey B Geske,Sara Saberi,Andrew Wang,Mark Sherrid,Paul C Cremer,Neal K Lakdawala,Albree Tower-Rader,David Fermin,Srihari S Naidu,Nicholas G Smedira,Hartzell Schaff,Zhiqun Gong,Lana Mudarris,Kathy Lampl,Amy J Sehnert,Steven E Nissen,
BACKGROUND In severely symptomatic patients with obstructive hypertrophic cardiomyopathy (HCM), VALOR-HCM trial (Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy [URL: https://clinicaltrials.gov; Unique identifier: NCT04349072]) reported that mavacamten reduced the short-term need for septal reduction therapy (SRT). The current report
-
Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial). Circulation (IF 35.5) Pub Date : 2024-11-18 Yugo Yamashita,Takeshi Morimoto,Nao Muraoka,Wataru Shioyama,Ryuki Chatani,Tatsuhiro Shibata,Yuji Nishimoto,Yoshito Ogihara,Kosuke Doi,Maki Oi,Taro Shiga,Daisuke Sueta,Kitae Kim,Yasuhiro Tanabe,Norimichi Koitabashi,Takuma Takada,Satoshi Ikeda,Hitoshi Nakagawa,Kengo Tsukahara,Masaaki Shoji,Jiro Sakamoto,Shinji Hisatake,Yutaka Ogino,Masashi Fujita,Naohiko Nakanishi,Tomohiro Dohke,Seiichi Hiramori,Ryuzo
BACKGROUND The optimal duration of anticoagulation therapy for patients with cancer and acute low-risk pulmonary embolism (PE) is clinically relevant, but evidence is lacking. Prolonged anticoagulation therapy could have a potential benefit for prevention of thrombotic events; however, it could also increase the risk of bleeding. METHODS In a multicenter, open-label, adjudicator-blinded, randomized
-
Randomized Study Comparing a Novel Intranasal Formulation of Bumetanide to Oral and Intravenous Formulations. Circulation (IF 35.5) Pub Date : 2024-11-18 Andrew P Ambrosy,Daniel Bensimhon,Galina Bernstein,Brian Kolski,Joel Neutel,Benjamin Esque,Eric Adler
-
Semaglutide Eligibility Across All Current Indications for US Adults JAMA Cardiol. (IF 14.8) Pub Date : 2024-11-18 Ivy Shi, Sadiya S. Khan, Robert W. Yeh, Jennifer E. Ho, Issa J. Dahabreh, Dhruv S. Kazi
This cross-sectional study uses National Health and Nutrition Examination Survey data to examine the number of US adults eligible for semaglutide across all current indications.
-
Early Adoption of Sodium-Glucose Cotransporter-2 Inhibitor in Patients Hospitalized With Heart Failure With Mildly Reduced or Preserved Ejection Fraction JAMA Cardiol. (IF 14.8) Pub Date : 2024-11-18 Mohammad Abdel Jawad, John A. Spertus, Uchechukwu Ikeaba, Stephen J. Greene, Gregg C. Fonarow, Karen Chiswell, Paul S. Chan
ImportanceSodium-glucose cotransporter-2 inhibitors (SGLT2is) are the first therapy shown to improve clinical outcomes for patients with heart failure (HF) and a left ventricular ejection fraction (LVEF) greater than 40%. Nationwide adoption of SGLT2is in the US since publication of the Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction (EMPEROR-Preserved)
-
C-C motif chemokine receptor-2 blockade ameliorates pulmonary hypertension in rats and synergizes with a pulmonary vasodilator Cardiovasc. Res. (IF 10.2) Pub Date : 2024-11-18 Naoki Tsuboya, Hirofumi Sawada, Yoshihide Mitani, Hironori Oshita, Kazunobu Ohya, Mami Takeoka, Jane Chanda Kabwe, Yoshiki Miyasaka, Hiromasa Ito, Noriko Yodoya, Hiroyuki Ohashi, Junko Maruyama, Ryuji Okamoto, Tomoji Mashimo, Kaoru Dohi, Yuhei Nishimura, Kazuo Maruyama, Masahiro Hirayama
Aims We investigated whether the disruption of C-C motif chemokine receptor (CCR) 2 may attenuate the development of pulmonary arterial hypertension (PAH) in any rat models with the reversal of the associated pro-inflammatory state and vascular dysfunction, and synergize with a conventional pulmonary vasodilator. Methods and Results Using Ccr2(-/-) rats generated by CRISPR/Cas9, we investigated pulmonary
-
The Fine Art and Science of Translating Trials Results Into Clinical Practice. JAMA Cardiol. (IF 14.8) Pub Date : 2024-11-17 Gregg C Fonarow,Eric D Peterson,Adrian F Hernandez
-
Sex-Specific Efficacy and Safety in HF Trials: Inclusion Is Only the First Step. JAMA Cardiol. (IF 14.8) Pub Date : 2024-11-17 Sadiya Khan,Clyde W Yancy,Gregg C Fonarow
-
Power of Digital Nudges to Boost Influenza Vaccination Rates. JAMA Cardiol. (IF 14.8) Pub Date : 2024-11-17 Mohammad Madjid,Payam Safavi-Naeini
-
Finerenone, Serum Potassium, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction JAMA Cardiol. (IF 14.8) Pub Date : 2024-11-17 Orly Vardeny, Muthiah Vaduganathan, Brian L. Claggett, Akshay S. Desai, Pardeep S. Jhund, Carolyn S. P. Lam, Michele Senni, Sanjiv J. Shah, Adriaan A. Voors, Faiez Zannad, Bertram Pitt, Shingo Matsumoto, Béla Merkely, Shelley Zieroth, Mehmet Birhan Yilmaz, James Lay-Flurrie, Prabhakar Viswanathan, Andrea Horvat-Broecker, Andrea Scalise, John J. V. McMurray, Scott D. Solomon
ImportanceTreatment with finerenone, a nonsteroidal mineralocorticoid receptor antagonist (MRA), improved outcomes in patients with heart failure with mildly reduced or preserved ejection fraction in FINEARTS-HF, but was associated with increased levels of serum potassium in follow-up.ObjectiveTo investigate the frequency and predictors of serum potassium level greater than 5.5 mmol/L and less than